Pyxis Oncology, Inc. (PYXS) earnings
PYXS earnings moved a median of +2.03% by the close. Quarterly and annual PYXS reports and results, each read against the price at its own news timestamp. Back to the PYXS overview →
21 measured PYXS earnings events.
Where these PYXS earnings landedvs 21 measured PYXS earnings reactions
| Middle 50% of PYXS earnings reactions | -2.53% to +4.22% |
|---|---|
| Median reaction (to close) | +2.03% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 PYXS earnings events with a measured close landed between -2.53% and +4.22%; 62% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Pyxis Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | +2.03% | +2.03% | |
| Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones | Press release | +2.03% | +2.03% | |
| Form 10-Q Pyxis Oncology, Inc. For: Mar 31 | SEC filing · Form 10-Q | -13.21% | -16.60% | |
| Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones | Press release | -13.21% | -16.60% | |
| Form 10-K Pyxis Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.67% | -5.33% | |
| Form 10-Q Pyxis Oncology, Inc. For: Sep 30 | SEC filing · Form 10-Q | +4.60% | +9.48% | |
| Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results | Press release | +4.60% | +9.48% | |
| Form 10-Q Pyxis Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +6.96% | |
| Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | +0.00% | +6.96% | |
| Form 10-Q Pyxis Oncology, Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.85% | +2.78% | |
| Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | -1.85% | +2.78% | |
| Form 10-K Pyxis Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | -9.68% | -14.52% | |
| Form 10-Q Pyxis Oncology, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.21% | -2.53% | |
| Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024 | Press release | +2.82% | +0.22% | |
| Form 10-Q Pyxis Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | +5.11% | +3.00% | |
| Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024 | Press release | +5.11% | +3.00% | |
| Form 10-Q Pyxis Oncology, Inc. For: Mar 31 | SEC filing · Form 10-Q | +6.58% | +4.22% | |
| Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024 | Press release | +6.58% | +4.22% | |
| Form 10-K Pyxis Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | +4.67% | -19.07% | |
| Form 10-Q Pyxis Oncology, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.60% | -1.81% | |
| Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update | Press release | -0.60% | -1.81% |
Keep exploring
More PYXS: analyst actions → · SEC filings → · PYXS overview →